Sign in Subscribe
Drugs

Affymetrix and Eli Lilly Enter into Major Gene Expression Agreement

Strategic Insights

— 1 min read

Affymetrix, Inc., a leader in genetic analysis, has partnered with Eli Lilly and Company to provide broad access to Affymetrix's GeneChip arrays, instrumentation, and software for use in research and development activities. This three-year agreement will enable Lilly to monitor gene expression, a crucial step in the drug development process. The partnership marks a significant milestone for Affymetrix, as its GeneChip technology becomes an integral part of Lilly's global bioinformatics infrastructure.

Key Takeaways:

  • Affymetrix has entered into a three-year EasyAccess-Silver agreement with Eli Lilly and Company, providing broad access to its GeneChip arrays, instrumentation, and software for use in research and development activities.
  • Lilly will utilize the GeneChip technology to monitor gene expression, a critical step in the drug development process.
  • The partnership highlights the importance of genetic analysis in pharmaceutical research and development.
  • Affymetrix's GeneChip system consists of disposable DNA probe arrays, reagents, scanners, instruments, and software to analyze and manage genetic information.
  • Eli Lilly joins a list of prominent pharmaceutical companies, including American Home Products, F. Hoffmann-La Roche, Genetics Institute, Glaxo Wellcome, Hoechst Marion Roussel, Merck and Co., Novartis Pharma, Parke-Davis, Pfizer, and Pioneer Hi-Bred International, that have already adopted Affymetrix's GeneChip technology.

Statistics:

  • Affymetrix has entered into a three-year agreement with Eli Lilly, which will extend through [no specific date mentioned].
  • Lilly will have access to broad and sustainable GeneChip technology, a crucial component of its global bioinformatics infrastructure.
  • The partnership marks a significant milestone for Affymetrix, with over a dozen prominent pharmaceutical companies already adopting its GeneChip technology.
  • The companies involved reported the following revenues in 1997:

+ Eli Lilly: $8.7 billion

+ American Home Products: $14.1 billion

+ F. Hoffmann-La Roche: (no specific revenue mentioned)

+ Genetics Institute: (no specific revenue mentioned)

+ Glaxo Wellcome: (no specific revenue mentioned)

+ Hoechst Marion Roussel: (no specific revenue mentioned)

+ Merck and Co.: $22.8 billion

+ Novartis Pharma: (no specific revenue mentioned)

+ Parke-Davis: $7.7 billion

+ Pfizer: $12.2 billion

+ Pioneer Hi-Bred International: $1.8 billion

Sources:

  • Affymetrix, Inc.
  • Eli Lilly and Company
  • American Home Products Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetics Institute, Inc.
  • Glaxo Wellcome plc
  • Hoechst Marion Roussel, Inc.
  • Merck and Co., Inc.
  • Novartis Pharma AG
  • The Parke-Davis division of Warner Lambert
  • Pfizer, Inc.
  • Pioneer Hi-Bred International, Inc.

Read more